ArticleFrontiers in bioinformatics2026
Integrating transcriptomic analysis to explore biomarkers and therapeutic targets for rheumatoid arthritis: a case-control and systems biology approach.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid Arthritis (RA) is a highly variable and unpredictable autoimmune disease, relying solely on physical symptoms often leads to delayed treatment and irreversible joint destruction. Therefore, identifying biomarkers in RA is necessary to bridge the gap between a patient's unique biological profile and successful clinical management. This study aims to identify distinct molecular signatures in RA patients by integrating systems biology and case-control methodologies. Methods: Transcriptomic datasets from various sources specifically synovial tissues, macrophages, blood, T-cells, natural killer T-cells, natural killer cells, neutrophils, and monocytes were analysed. Differentially Expressed Genes and functional enrichment pathways were identified, followed by Weighted Gene Co-expression Network Analysis to pinpoint hub genes. Machine learning models were used to extract consensus biomarkers. Two of the predicted biomarkers IL2RG) and Interferon-Gamma (IFNG) were further validated using an Enzyme-Linked Immunosorbent Assay (ELISA) in RA patient serum samples. Results: The analysis revealed that synovial tissues and synovial macrophages exhibited pronounced transcriptomic expression changes. Six consensus biomarkers such as IFNG, PTEN, IL2RG, CDKN2D, VEGFA, and CDKN1A were computationally prioritized in synovial macrophages. Among these, IL2RG and IFNG were selected for preliminary experimental validation by ELISA. IL2RG concentrations were significantly higher in RA patients (1.34 ± 0.11 ng/mL) than in healthy controls (0.83 ± 0.07 ng/mL), while IFNG levels showed only a marginal increase (1.91 ± 0.06 pg/mL) compared to controls (1.69 ± 0.06 pg/mL). Conclusion: By integrating multi-tissue transcriptomic profiling with machine learning, this study mapped critical molecular changes in RA and prioritized six consensus biomarkers within synovial macrophages. Experimental validation confirmed that IL2RG and IFNG are significantly elevated in RA patients compared to healthy controls. These findings offer a promising, minimally invasive molecular markers for diagnosis and personalized clinical management in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.